Glenmark Pharmaceuticals to launch DCGI-approved BRUKINSA in India for treatment of hematological malignancies
Globally, BRUKINSA is approved in more than 70 countries
Globally, BRUKINSA is approved in more than 70 countries
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
The 16,000-square-foot expansion enhances DuPont’s global sterile operations
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
33rd lab in Thyrocare’s expanding network to bring advanced, affordable diagnostic services across the Kashmir Valley
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
Subscribe To Our Newsletter & Stay Updated